What is Arcus Biosciences?
Founded in 2015, Arcus Biosciences operates as a global, clinical-stage biopharmaceutical entity dedicated to the discovery and development of differentiated molecules and combination therapies. The company distinguishes itself through a rigorous scientific approach, targeting well-understood biological pathways to engineer medicines that offer superior safety and efficacy profiles compared to existing standards of care. With a multidisciplinary team of scientists and clinical experts, Arcus is strategically positioned to disrupt the oncology market by focusing on high-impact therapeutic interventions that address unmet patient requirements in cancer treatment.
How much funding has Arcus Biosciences raised?
Arcus Biosciences has raised a total of $250M across 1 funding round:
Debt
$250M
Debt (2024): $250M with participation from Hercules Capital
Key Investors in Arcus Biosciences
Hercules Capital
Hercules Capital is a specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology, life sciences and sustainable and renewable technology industries.
What's next for Arcus Biosciences?
With the recent influx of capital, Arcus Biosciences is well-positioned to accelerate its clinical development programs and expand its research capabilities. The strategic deployment of these funds will likely focus on scaling the testing of its lead candidates and optimizing combination therapy protocols. As the company transitions through this major enterprise-level funding phase, stakeholders will be monitoring the progression of its pipeline through late-stage clinical trials. The focus remains on achieving key regulatory milestones and establishing the company as a leader in the next generation of cancer therapeutics, leveraging its strengthened balance sheet to navigate the complexities of global drug development and commercialization.
See full Arcus Biosciences company page
